Phogen
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Phogen
Antikor Takes Aim At Solid Tumors With Antibody-Fragment Conjugates
Emerging Company Profile: The UK's Antikor Biopharma is advancing antibody fragment-drug conjugates (FDCs) closer to the clinic with plans for its first human study in 2019 or 2020.
Spine Market: Are the Good Times Over?
The global market for spine implants and products will surpass $6 billion this year. While technological innovations continue to abound and industry proponents forecast sustained double-digit growth, the spine market is entering an unsettling phase of bureaucratic regulation and oversight from regulators and payors who appear intent on putting the breaks on this sector.
The Hot Trend in Spine: Motion Preservation Mania
While products for fusing the spine remain the backbone of the booming market for spinal implants and instruments, there's a new focus on motion preservation. These technologies--for lumbar and cervical disc replacement, nucleus replacement, posterior stabilization,and pedicle screw-based systems--promise a host of new procedures to treat patients with symptomatic back pain who are earlier in the degenerative process.
Spine Update: BMP Use Continues to Expand
Medtronic recently declared that InFUSE, the company's blockbuster spine bone graft product that provides the growth factor rhBMP-2 as part of a lumbar fusion cage, was well on its way to becoming standard of care in spine surgery. The company's success has fueled interest in a plethora of potential entrants into the biologic bone formation market.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice